The telomeric PARP, tankyrases, as targets for cancer therapy

The requirement for the maintenance of telomeres by telomerase by most cancer cells for continued proliferation is a target in anticancer strategies. Tankyrases are poly(ADP-ribose) polymerases that enhance telomerase access to telomeres. Tankyrase 1 modulates telomerase inhibition in human cancer c...

Descripción completa

Detalles Bibliográficos
Autor principal: Seimiya, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361147/
https://www.ncbi.nlm.nih.gov/pubmed/16421589
http://dx.doi.org/10.1038/sj.bjc.6602951
_version_ 1782153149155377152
author Seimiya, H
author_facet Seimiya, H
author_sort Seimiya, H
collection PubMed
description The requirement for the maintenance of telomeres by telomerase by most cancer cells for continued proliferation is a target in anticancer strategies. Tankyrases are poly(ADP-ribose) polymerases that enhance telomerase access to telomeres. Tankyrase 1 modulates telomerase inhibition in human cancer cells and is reviewed in this report as a potential telomere-directed anticancer target.
format Text
id pubmed-2361147
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23611472009-09-10 The telomeric PARP, tankyrases, as targets for cancer therapy Seimiya, H Br J Cancer Minireview The requirement for the maintenance of telomeres by telomerase by most cancer cells for continued proliferation is a target in anticancer strategies. Tankyrases are poly(ADP-ribose) polymerases that enhance telomerase access to telomeres. Tankyrase 1 modulates telomerase inhibition in human cancer cells and is reviewed in this report as a potential telomere-directed anticancer target. Nature Publishing Group 2006-02-13 2006-01-17 /pmc/articles/PMC2361147/ /pubmed/16421589 http://dx.doi.org/10.1038/sj.bjc.6602951 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Minireview
Seimiya, H
The telomeric PARP, tankyrases, as targets for cancer therapy
title The telomeric PARP, tankyrases, as targets for cancer therapy
title_full The telomeric PARP, tankyrases, as targets for cancer therapy
title_fullStr The telomeric PARP, tankyrases, as targets for cancer therapy
title_full_unstemmed The telomeric PARP, tankyrases, as targets for cancer therapy
title_short The telomeric PARP, tankyrases, as targets for cancer therapy
title_sort telomeric parp, tankyrases, as targets for cancer therapy
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361147/
https://www.ncbi.nlm.nih.gov/pubmed/16421589
http://dx.doi.org/10.1038/sj.bjc.6602951
work_keys_str_mv AT seimiyah thetelomericparptankyrasesastargetsforcancertherapy
AT seimiyah telomericparptankyrasesastargetsforcancertherapy

Ejemplares similares